SG11202004642YA - An agent for treating nocturnal pollakiuria - Google Patents
An agent for treating nocturnal pollakiuriaInfo
- Publication number
- SG11202004642YA SG11202004642YA SG11202004642YA SG11202004642YA SG11202004642YA SG 11202004642Y A SG11202004642Y A SG 11202004642YA SG 11202004642Y A SG11202004642Y A SG 11202004642YA SG 11202004642Y A SG11202004642Y A SG 11202004642YA SG 11202004642Y A SG11202004642Y A SG 11202004642YA
- Authority
- SG
- Singapore
- Prior art keywords
- agent
- treating nocturnal
- nocturnal pollakiuria
- pollakiuria
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017244910 | 2017-12-21 | ||
| JP2018212256 | 2018-11-12 | ||
| PCT/JP2018/047038 WO2019124507A1 (en) | 2017-12-21 | 2018-12-20 | Therapeutic agent for nocturnal pollakiuria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202004642YA true SG11202004642YA (en) | 2020-06-29 |
Family
ID=66992682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202004642YA SG11202004642YA (en) | 2017-12-21 | 2018-12-20 | An agent for treating nocturnal pollakiuria |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11376253B2 (en) |
| EP (1) | EP3730141A4 (en) |
| JP (1) | JP7291632B2 (en) |
| KR (1) | KR20200103034A (en) |
| CN (2) | CN111556753A (en) |
| CA (1) | CA3085745A1 (en) |
| PH (1) | PH12020550756A1 (en) |
| SG (1) | SG11202004642YA (en) |
| TW (2) | TWI802623B (en) |
| WO (1) | WO2019124507A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111556753A (en) * | 2017-12-21 | 2020-08-18 | 杏林制药株式会社 | Therapeutic agent for nocturnal pollakisuria |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| CA2695634C (en) * | 2007-08-06 | 2018-01-23 | Serenity Pharmaceuticals Corporation | Methods and devices for desmopressin drug delivery |
| PE20091825A1 (en) | 2008-04-04 | 2009-12-04 | Merck & Co Inc | HYDROXIMETHYL PYRROLIDINES AS AGONISTS OF THE BETA 3 ADRENERGIC RECEPTOR |
| NZ599233A (en) * | 2009-10-07 | 2013-04-26 | Merck Sharp & Dohme | Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent |
| EP3210969B1 (en) * | 2014-10-24 | 2021-04-28 | ONO Pharmaceutical Co., Ltd. | Kcnq2-5 channel activator |
| WO2017210696A1 (en) * | 2016-06-03 | 2017-12-07 | Velicept Therapeutics, Inc. | Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder |
| AU2018282104A1 (en) * | 2017-06-06 | 2019-12-12 | Urovant Sciences Gmbh | Use of vibegron to treat overactive bladder |
| AU2018282105A1 (en) * | 2017-06-06 | 2019-12-12 | Urovant Sciences Gmbh | Dosing of vibegron for treatment of overactive bladder |
| CN111556753A (en) * | 2017-12-21 | 2020-08-18 | 杏林制药株式会社 | Therapeutic agent for nocturnal pollakisuria |
-
2018
- 2018-12-20 CN CN201880082431.3A patent/CN111556753A/en active Pending
- 2018-12-20 SG SG11202004642YA patent/SG11202004642YA/en unknown
- 2018-12-20 US US16/768,972 patent/US11376253B2/en active Active
- 2018-12-20 KR KR1020207020619A patent/KR20200103034A/en active Search and Examination
- 2018-12-20 EP EP18890939.4A patent/EP3730141A4/en active Pending
- 2018-12-20 CN CN202410227518.2A patent/CN118078835A/en active Pending
- 2018-12-20 CA CA3085745A patent/CA3085745A1/en active Pending
- 2018-12-20 WO PCT/JP2018/047038 patent/WO2019124507A1/en unknown
- 2018-12-20 JP JP2019560567A patent/JP7291632B2/en active Active
- 2018-12-21 TW TW107146477A patent/TWI802623B/en active
- 2018-12-21 TW TW112114485A patent/TW202333733A/en unknown
-
2020
- 2020-05-22 PH PH12020550756A patent/PH12020550756A1/en unknown
-
2022
- 2022-05-31 US US17/828,681 patent/US20220347181A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111556753A (en) | 2020-08-18 |
| US11376253B2 (en) | 2022-07-05 |
| WO2019124507A1 (en) | 2019-06-27 |
| JP7291632B2 (en) | 2023-06-15 |
| EP3730141A4 (en) | 2021-10-13 |
| US20210000831A1 (en) | 2021-01-07 |
| JPWO2019124507A1 (en) | 2020-12-10 |
| PH12020550756A1 (en) | 2021-05-17 |
| TW202333733A (en) | 2023-09-01 |
| TW201929859A (en) | 2019-08-01 |
| EP3730141A1 (en) | 2020-10-28 |
| CA3085745A1 (en) | 2019-06-27 |
| CN118078835A (en) | 2024-05-28 |
| TWI802623B (en) | 2023-05-21 |
| KR20200103034A (en) | 2020-09-01 |
| US20220347181A1 (en) | 2022-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201715639D0 (en) | Compositions for wound treatment | |
| IL251215A0 (en) | Cannabinoid composition and method for treating pain | |
| EP3634369C0 (en) | Methods for treating chemically relaxed hair | |
| EP3618783C0 (en) | Devices for treating eyelids | |
| SG11201704499WA (en) | Agent for hair deforming treatment | |
| SG11201704497PA (en) | Agent for hair deforming treatment | |
| GB201714871D0 (en) | Treatment method | |
| ZA201907973B (en) | Agent for preventing or treating brain atrophy | |
| ZA201906047B (en) | Compounds for treating tuberculosis | |
| EP3507838C0 (en) | Device for treating parts | |
| SG11201704504PA (en) | Agent for hair deforming treatment | |
| HK1255224A1 (en) | Wound treatment agent | |
| PL3691649T3 (en) | Compositions and methods for wound treatment | |
| GB201819924D0 (en) | Treatment method | |
| IL271923A (en) | Methods and compositions for treating addictions | |
| SG11201704493UA (en) | Agent for hair deforming treatment | |
| HK1248130A1 (en) | Composition for treating pain | |
| IL271211A (en) | Treatment for migraine | |
| IL261958A (en) | Formulations for treating constipation | |
| SG11202003127WA (en) | Methods for treating lymphomas | |
| GB201714777D0 (en) | Agent | |
| SG11202004642YA (en) | An agent for treating nocturnal pollakiuria | |
| IL271967A (en) | Methods for treating congenital hyperinsulinism | |
| GB201715101D0 (en) | Protection apparatus | |
| IL268715A (en) | Compositions for treating acne |